Melanoma Cancer Clinical Trial
State of the question Over the past decade, the incidence of melanoma (MM) has steadily
increased in France and in most developed countries. This increased incidence was concerned
mainly MM thin while the incidence of MM thick that represent the true "killers", and
mortality from MM remained stable or increased slightly over the same period. These
epidemiological data and observations from everyday medical practice dermatologists suggest
the existence of different growth patterns within MM. Indeed, some MM progressing slowly
sometimes for decades before diagnosis but are thin at the time of resection. Conversely,
others MM grow very quickly, resulting in thick tumors despite a diagnosis and resection
sometimes very early. These fast growing MM (FGMM) probably contribute significantly to the
relative mortality in MM, as improved screening failed to influence to this day.
Our team has already demonstrated that the growth kinetics of the MM was a prognostic factor
of tumor aggressiveness regardless of the thickness of the tumor. Using the same method to
calculate the growth rate, an Australian team recently studied the growth rate in a
population of patients suffering from MM. In this population 1/3 of MM had a growth of more
than 0.5 mm per month. Clinical aspects and FGMM of these risk factors were individuals
(injuries symmetrical achromic and regular occurrence among about older and low-nevi). The
European and Australian people are very different in particular regarding the prevention
policy, these results can not be extrapolated to the French population.The main objective is
to identify risk factors for FGMM in French propulation
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01703585 -
Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples
|
||
| Recruiting |
NCT03693014 -
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
|
Phase 2 | |
| Active, not recruiting |
NCT04152018 -
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
|
Phase 1 |